Dora Puhakka was a Speaker at TEDxEspoo Youth 2025! What does it truly mean to connect with another human being? In this TEDx Talk, Dora Puhakka invites us to reflect on one of the most universal human needs: to be seen, to be heard, and to feel that we belong. From the beginning of the Talk we are reminded that human connection is not a luxury - it is a necessity. Yet despite living in an increasingly interconnected world, many of us feel isolated, divided, and misunderstood. This Talk explores how concept ...

Key Takeaways ETR plans to invest $37B by 2028 to upgrade grid infrastructure and expand renewable energy. Entergy's 2025 sales are expected to grow 5.6% year over year, with 9.5% long-term earnings growth. ETR shares have gained 52.3% in the past year, far outpacing the utility industry's 16.6% growth.Entergy Corporation (ETR) focuses on consistent investments in infrastructure upgrades to better serve its customers. The company is also steadily expanding its renewable generation portfolio. Given its str ...

Core Viewpoint - Apollo has agreed to sell its interest in MAFTEC Group Co., Ltd., a leader in ultra-high temperature heat insulating solutions, to funds managed by Advantage Partners, with the transaction expected to close in the second half of 2025 [1][5]. Company Overview - MAFTEC was established from the separation of Mitsubishi Chemical's Thermal and Emission Control Materials business, which Apollo acquired in March 2022 [2]. - Apollo played a crucial role in MAFTEC's product development and market establishment, contributing to significant EBITDA growth over the past three years [2][3]. Management Insights - Tetsuji Okamoto from Apollo expressed pride in MAFTEC's achievements and confidence in its long-term growth potential, highlighting the company's innovative material processing technology [3]. - Kosuke Matsuzaki, CEO of MAFTEC, acknowledged Apollo's support in executing the company's standalone strategy and expressed optimism about future collaboration with Advantage Partners [4]. Investment Strategy - The investment in MAFTEC reflects Apollo's strategy as a solution provider and strategic partner to leading Japanese conglomerates, with previous investments including Panasonic Automotive Systems and Altemira [4].

Uh here to go out on that limb is Shri Kumar, the president of Shrikumar Global Strategy. Shri, it's great to have you back. Good to be back, Kelly.And yes, I am going out on a limb and on a record day to be talking about a 10% correction coming by the end of the year. But the various macro factors that I'm looking at seems to suggest that there is no way this situation can continue. What are they.We are looking at truths in a sense in three different areas. One is the Iran um and Israel war. The second is ...

Let's talk about M&A in the tech landscape. We're joined by Paul Weiss, global co-head of M&A, Krishna Veera Raghavan, and also Bloomberg's Michele Davis is on the M&A team. I think we should start, Christine, with what is happening.Most recently, I see the headlines dominated with the mechanism of the acqui-hire The most evident example recently has been matter in scale. I what are you seeing in acqui-hire as a mechanism on why we see in AI in particular several companies go down that route. I think it's a ...

Group 1 - The service Beyond the Wall Investing offers significant savings on equity research reports, potentially saving thousands of dollars annually for subscribers [1] - The investing group provides a fundamentals-based portfolio, weekly insights from institutional investors, and alerts for short-term trade ideas based on technical signals [2] - Community engagement is facilitated through ticker feedback requests and chat features, enhancing the overall investment experience [2] Group 2 - The article emphasizes that past performance does not guarantee future results, highlighting the importance of independent analysis [3] - It clarifies that no specific investment recommendations are provided, and opinions expressed may not reflect the views of the broader platform [3] - The authors of the analysis may not be licensed or certified, indicating a diverse range of contributors from both professional and individual investor backgrounds [3]

Core Viewpoint - SeaStar Medical Holding Corporation has undertaken several transactions to ensure compliance with Nasdaq's continued listing standards after receiving a notification regarding non-compliance with market value requirements [2][3]. Group 1: Compliance and Financial Transactions - SeaStar Medical received a notification from Nasdaq on June 24, 2024, indicating non-compliance with the minimum market value requirement of $35 million [2]. - The Nasdaq Hearings Panel granted an extension until June 22, 2025, for the company to demonstrate compliance with an alternative requirement of $2.5 million in stockholders' equity [2]. - The company completed a $4.0 million public offering of common stock and warrants on June 23, 2025, and entered into a purchase agreement with Lincoln Park Capital for up to $15.0 million in common stock purchases over three years [6]. Group 2: Business Operations and Product Development - SeaStar Medical increased its customer count to six for its FDA-approved product, QUELIMMUNE, which reduces pediatric mortality by approximately 50% in patients with multiple organ failure [3][4]. - The company initiated a cost-cutting program in May 2025, expected to reduce operating expenses for the remainder of the fiscal year without materially impacting operations [3]. - Approximately $1.2 million in employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to unpaid bonuses and fees [3]. Group 3: Product Overview and Clinical Trials - QUELIMMUNE therapy is designed for children with acute kidney injury (AKI) and sepsis, approved under a Humanitarian Device Exemption in February 2024, and launched commercially in July 2024 [4][10]. - The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of the Selective Cytopheretic Device (SCD) therapy in 200 adults with AKI, focusing on 90-day mortality and dialysis dependency as primary endpoints [7]. - The SCD therapy aims to neutralize over-active immune cells and mitigate hyperinflammation, with potential applications in various acute and chronic kidney and cardiovascular diseases [9][10].

hyperliquid will have more equity derivative markets than crypto perps by Q4 2026 ...

Company Overview - LifeMD (NASDAQ: LFMD) has a unique corporate structure, originally founded as ImmuDyne in 1994 and going public in 2001, later rebranding to Conversion Labs in 2018 before adopting its current name [1] Investment Approach - The investment strategy focuses on a holistic approach that incorporates both top-down and bottom-up valuation techniques, emphasizing the importance of detailed company aspects such as capital structure and debt covenants in equity valuation [1]

Core Insights - AppLovin Corporation is establishing itself as a strong player in mobile advertising through three interconnected factors that provide sustainable competitive advantages [1] Group 1: Company Overview - AppLovin utilizes an AI-based advertising engine as its technology-centric platform [1] - The company focuses on long/short equity strategies, conducting deep fundamental analysis to identify undervalued stocks for long positions and overvalued stocks for short positions in global equity markets [1] Group 2: Financial Analysis - AppLovin builds detailed financial models using discounted cash flow (DCF), relative valuation, and scenario analysis to assess company fundamentals, growth potential, and risks [1] - The company delivers high-conviction investment recommendations through comprehensive research, contributing to alpha generation for the fund [1] Group 3: Market Strategy - AppLovin monitors market trends, sector dynamics, and macroeconomic factors to adjust strategies and optimize portfolio performance in real time [1] - The company collaborates with the Portfolio Manager to size positions, manage risk exposure, and navigate challenges such as short squeezes or market volatility [1]